Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0453474/Gout-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory
Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Gout Therapeutics market. The report identifies the key trends shaping and driving the global Gout Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gout Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Gout Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gout Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Gout Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gout Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Gout Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Gout Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gout Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Gout Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Gout Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Classification 7
2.2.1 Acute Gout 7
2.2.2 Chronic Gout 7
2.3 Epidemiology 8
2.3.1 Historic Epidemiology (2006-2011) 8
2.3.2 Forecast Epidemiology (2011-2019) 8
2.4 Prognosis 9
2.4.1 Progressions of Gout can be Divided into Four Phases 9
2.5 Pathophysiology 10
2.6 Signs and Symptoms 11
2.7 Diagnosis 11
2.7.1 Laboratory Diagnosis Tests 12
2.8 Treatment and Management Options 12
2.8.1 Treatment of Gout in the US 13
2.8.2 Treatment of Gout in Europe 15
2.8.3 Treatment of Gout in Japan 17
2.9 Referral Pathway 18
2.9.1 Referral Pathway in the US 18
2.9.2 Referral Pathway in the Europe 18
2.9.3 Referral Pathway in Japan 18
2.10 GlobalData Pipeline Report Guidance 19
2.11 KOL Insights 20
3 Gout Therapeutics - Market Characterization 21
3.1 Gout Therapeutics Market Size (2006-2011) – Global 21
3.2 Gout Therapeutics Market Forecast (2011-2019) – Global 22
3.3 Gout Therapeutics Market Size (2006-2011) – The US 23
3.4 Gout Therapeutics Market Forecast (2011-2019) – The US 24
3.5 Gout Therapeutics Market Size (2006-2011) – France 25
3.6 Gout Therapeutics Market Forecast (2011-2019) – France 26
3.7 Gout Therapeutics Market Size (2006-2011) – Germany 27
3.8 Gout Therapeutics Market Forecast (2011-2019) – Germany 28
3.9 Gout Therapeutics Market Size (2006-2011) – Italy 29
3.10 Gout Therapeutics Market Forecast (2011-2019) – Italy 30
3.11 Gout Therapeutics Market Size (2006-2011) – Spain 31
3.12 Gout Therapeutics Market Forecast (2011-2019) - Spain 32
3.13 Gout Therapeutics Market Size (2006-2011) – The UK 33
3.14 Gout Therapeutics Market Forecast (2011-2019) – The UK 34
3.15 Gout Therapeutics Market Size (2006-2011) – Japan 35
3.16 Gout Therapeutics Market Forecast (2011-2019) – Japan 36
3.17 Drivers and Barriers for the Gout Therapeutics Market 37
3.17.1 Drivers for the Gout Therapeutics Market 37
3.17.2 Expected Launch of Three Drugs and Consequent Increase in Cost of Therapy 37
3.17.3 Barriers for the Gout Therapeutics Market 37
3.18 Opportunity and Unmet Need Analysis 38
3.19 KOL Insight: 40
3.20 Key Takeaway 40
4 Gout Therapeutics - Competitive Assessment 41
4.1 Overview 41
4.2 Strategic Competitor Assessment 41
4.3 Product Profiles for the Major Marketed Classes of Products 42
4.3.1 NSAIDs 42
4.3.2 Corticosteroids 43
4.3.3 Colcrys (Colchicines) 43
4.3.4 Allopurinol 44
4.3.5 Probenecid 44
4.3.6 Uloric, Adenuric (febuxostat) 45
4.3.7 Krystexxa (Pegloticase) 46
4.4 KOL Insights 47
4.5 Key Takeaway 47
5 Gout Therapeutics - Pipeline Assessment 48
5.1 Overview 48
5.2 Strategic Pipeline Assessment 48
5.3 Gout Therapeutics Pipeline – Pipeline by Phases of Development 48
5.3.1 Gout Therapeutics – Pre-Registration Phase Pipeline 48
5.3.2 Gout Therapeutics – Phase III Pipeline 49
5.3.3 Gout Therapeutics – Phase II Pipeline 49
5.3.4 Gout Therapeutics – Phase I Pipeline 49
5.3.5 Gout Therapeutics – Pre-Clinical Pipeline 49
5.3.6 Gout Therapeutics – Discovery 50
5.3.7 Technology Trends Analytic Framework 50
5.4 Gout Therapeutics Market – Clinical Pipeline by Mechanism of Action 52
5.5 Gout Therapeutics – Promising Drugs Under Clinical Development 53
5.5.1 Arcalyst (Rilonacept) 53
5.5.2 Ilaris (ACZ885) 54
5.5.3 Lesinurad (RDEA594) 55
5.6 KOL Insights 56
5.7 Key Takeaway 56
6 Gout Therapeutics - Clinical Trials Mapping 57
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 57
6.2 Clinical Trials by Phase 58
6.3 Clinical Trials by Trial Status 59
6.4 Prominent Sponsors 60
6.5 Clinical Trials by Overall Sponsors 61
6.6 Top Companies Participating in Gout Therapeutics Clinical Trials 62
7 Gout Therapeutics - Strategic Assessment 63
7.1 Key Events Impacting the Future Market 63
7.2 Gout Therapeutics: Implications for Future Market Competition 64
8 Gout Therapeutics - Future Players 65
8.1 Introduction 65
8.2 Company Profiles 66
8.2.1 Regeneron Pharmaceuticals, Inc. 66
8.2.2 Novartis AG 66
8.2.3 Ardea Biosciences, Inc 67
8.2.4 Other Companies in the Market 68
9 Gout Therapeutics - Licensing and Partnership Deals 70
10 KOL Insights 74
11 Gout Therapeutics - Appendix 75
11.1 Market Definitions 75
11.2 Abbreviations 75
11.3 Bibliography 76
11.4 Research Methodology 76
11.4.1 Coverage 76
11.4.2 Secondary Research 77
11.4.3 Forecasting 77
11.4.4 Primary Research 79
11.4.5 Expert Panel Validation 80
11.5 Contact Us 80
11.6 Disclaimer 80
List of Tables
Table 1: Gout Prevalence in the Targeted Countries, 2006-2011 8
Table 2: Gout Prevalence in the Targeted Countries, 2011-2019 8
Table 3: Pharmacologic Options for Urate-Lowering Therapy in Patients with Chronic Gout 14
Table 4: Pharmacologic Options for Urate-Lowering Therapy in Patients with Chronic Gout 14
Table 5: Gout Therapeutics Market, Global, Revenue ($m), 2006–2011 21
Table 6: Gout Therapeutics Market, Global, Forecast ($m), 2011–2019 22
Table 7: Gout Therapeutics Market, The US, Revenue ($m), 2006–2011 23
Table 8: Gout Therapeutics Market, The US, Forecast ($m), 2011–2019 24
Table 9: Gout Therapeutics Market, France, Revenue ($m), 2006–2011 25
Table 10: Gout Therapeutics Market, France, Forecast ($m), 2011–2019 26
Table 11: Gout Therapeutics Market, Germany, Revenue ($m), 2006–2011 27
Table 12: Gout Therapeutics Market, Germany, Forecast ($m), 2011–2019 28
Table 13: Gout Therapeutics Market, Italy, Revenue ($m), 2006–2011 29
Table 14: Gout Therapeutics Market, Italy, Forecast ($m), 2011–2019 30
Table 15: Gout Therapeutics Market, Spain, Revenue ($m), 2006–2011 31
Table 16: Gout Therapeutics Market, Spain, Forecast ($m), 2011–2019 32
Table 17: Gout Therapeutics Market, The UK, Revenue ($m), 2006–2011 33
Table 18: Gout Therapeutics Market, The UK, Forecast ($m), 2011–2019 34
Table 19: Gout Therapeutics Market, Japan, Revenue ($m), 2006–2011 35
Table 20: Gout Therapeutics Market, Japan, Forecast ($m), 2011–2019 36
Table 21: Gout Therapeutics – Pre-Registration Phase Pipeline, 2012 48
Table 22: Gout Therapeutics – Phase III Pipeline, as of January 2012 49
Table 23: Gout Therapeutics – Phase II Pipeline, 2012 49
Table 24: Gout Therapeutics – Phase I Pipeline, 2012 49
Table 25: Gout Therapeutics – Pre-Clinical Pipeline, 2012 49
Table 26: Gout Therapeutics – Discovery Pipeline, 2012 50
Table 27: Gout Therapeutics – Promising Pipeline Drugs, 2012 55
Table 28: Gout Therapeutics Market – Clinical Trials by Region/Country, 2012 57
Table 29: Gout Therapeutics – Clinical Trials by Phase, 2012 58
Table 30: Gout Therapeutics – Clinical Trials by Status, 2012 59
Table 31: Gout Therapeutics – Prominent Sponsors, 2012 60
Table 32: Gout Therapeutics – Overall Sponsors, 2012 61
Table 33: Gout Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2012 62
Table 34: Regeneron Pharmaceuticals, Inc, Gout Therapeutics Pipeline, 2012 66
Table 35: Novartis – Gout Therapeutics Pipeline, 2012 67
Table 36: Anacor Pharmaceuticals – Gout Therapeutics Pipeline, 2012 67
Table 37: Gout Therapeutics Market – Future Players, 2012 68
Table 38: Gout Therapeutics, Global, Deals, 2012 70
List of Figures
Figure 1: Deposition of Urate Crystals and Bone Erosion in Gout 7
Figure 2: Patient Flow Diagram for Gout, 2011 9
Figure 3: Prognosis of Gout and its Management 10
Figure 4: Pathogenesis of Gout 11
Figure 5: Management Pathway for Gout 15
Figure 6: Treatment Algorithm for Acute Gout in Europe 16
Figure 7: Management Pathway for Gout in Japan 17
Figure 8: Gout Therapeutics – KOL Insights, 2012 20
Figure 9: Gout Therapeutics Market, Global, Revenue ($m), 2006–2011 21
Figure 10: Gout Therapeutics Market, Global, Forecast ($m), 2011–2019 22
Figure 11: Gout Therapeutics Market, The US, Revenue ($m), 2006–2011 23
Figure 12: Gout Therapeutics Market, The US, Forecast ($m), 2011–2019 24
Figure 13: Gout Therapeutics Market, France, Revenue ($m), 2006–2011 25
Figure 14: Gout Therapeutics Market, France, Forecast ($m), 2011–2019 26
Figure 15: Gout Therapeutics Market, Germany, Revenue ($m), 2006–2011 27
Figure 16: Gout Therapeutics Market, Germany, Forecast ($m), 2011–2019 28
Figure 17: Gout Therapeutics Market, Italy, Revenue ($m), 2006–2011 29
Figure 18: Gout Therapeutics Market, Italy, Forecast ($m), 2011–2019 30
Figure 19: Gout Therapeutics Market, Spain, Revenue ($m), 2006–2011 31
Figure 20: Gout Therapeutics Market, Spain, Forecast ($m), 2011–2019 32
Figure 21: Gout Therapeutics Market, The UK, Revenue ($m), 2006–2011 33
Figure 22: Gout Therapeutics Market, The UK, Forecast ($m), 2011–2019 34
Figure 23: Gout Therapeutics Market, Japan, Revenue ($m), 2006–2011 35
Figure 24: Gout Therapeutics Market, Japan, Forecast ($m), 2011–2019 36
Figure 25: Gout Therapeutics Market – Drivers and Barriers, 2012 38
Figure 26: Opportunity and Unmet Need in the Acute Gout Therapeutics Market, 2012 39
Figure 27: Opportunity and Unmet Need in the Chronic Gout Therapeutics Market, 2012 39
Figure 28: Gout Therapeutics – KOL Insights, 2012 40
Figure 29: Acute Gout Therapeutics – Strategic Competitor Assessment, 2012 41
Figure 30: Chronic Gout Therapeutics – Strategic Competitor Assessment, 2012 42
Figure 31: Gout Therapeutics – KOL Insights, 2012 47
Figure 32: Gout Therapeutics – Pipeline by Phase of Development, 2012 48
Figure 33: Gout Therapeutics – Technology Trends Analytics Framework, 2012 50
Figure 34: Gout Therapeutics – Technology Trends Analytics Framework – Description, 2012 51
Figure 35: Gout Therapeutics – Pipeline by Mechanism of Action, 2012 52
Figure 36: Gout Therapeutics – KOL Insights, 2012 56
Figure 37: Gout Therapeutics – Clinical Trials by Country, 2012 57
Figure 38: Gout Therapeutics – Clinical Trials by Phase, 2012 58
Figure 39: Gout Therapeutics – Clinical Trials by Status, 2012 59
Figure 40: Gout Therapeutics – Prominent Sponsors, 2012 60
Figure 41: Gout Therapeutics – Overall Sponsors, 2012 61
Figure 42: Gout Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2012 62
Figure 43: Gout Therapeutics – Impact Analysis, 2012 63
Figure 44: Implications for Future Market Competition in the Gout Therapeutics Market, 2012 64
Figure 45: Gout Therapeutics Market – Pipeline by Company, 2012 65
Figure 46: Gout Therapeutics – KOL Insights, 2012 74
Figure 47: GlobalData Market Size Estimation 78
Figure 48: GlobalData Market Forecasting Model 79
Companies mentioned
Regeneron Pharmaceuticals, Inc.
Novartis AG
Ardea Biosciences, Inc
Other Companies in the Market
To order this report:
: Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019
__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article